MCA stability tool

Check whether tablets and capsules are suitable for a multi-compartment compliance aid (MCA), and build a list to print.

Browse medicines A to Z

A (medicines beginning with A) B (medicines beginning with B) C (medicines beginning with C) D (medicines beginning with D) E (medicines beginning with E) F (medicines beginning with F) G (medicines beginning with G) H (medicines beginning with H) I (medicines beginning with I) K (medicines beginning with K) L (medicines beginning with L) M (medicines beginning with M) N (medicines beginning with N) O (medicines beginning with O) P (medicines beginning with P) Q (medicines beginning with Q) R (medicines beginning with R) S (medicines beginning with S) T (medicines beginning with T) U (medicines beginning with U) V (medicines beginning with V) W (medicines beginning with W) X (medicines beginning with X) Y (medicines beginning with Y) Z (medicines beginning with Z)

Medicines beginning with D

Dihydrocodeine

Dihydrocodeine 30mg tablets

Use with caution

Stability notes for Dihydrocodeine 30mg tablets

Protect from light. Moisture sensitive medicine. Store in airtight (sealed) MCA. Manufacturer recommends storing in original container. No stability data in MCAs available.

Provenance

This recommendation is based on the products dihydrocodeine 30mg tablets (Bristol Laboratories Ltd) and dihydrocodeine 30mg tablets (Accord-UK Ltd).

Suppliers (9) of Dihydrocodeine 30mg tablets
Dihydrocodeine 30mg tablets (A A H Pharmaceuticals Ltd)
Dihydrocodeine 30mg tablets (Accord-UK Ltd)
Dihydrocodeine 30mg tablets (Alliance Healthcare (Distribution) Ltd)
Dihydrocodeine 30mg tablets (Almus Pharmaceuticals Ltd)
Dihydrocodeine 30mg tablets (Bristol Laboratories Ltd)
Dihydrocodeine 30mg tablets (Crescent Pharma Ltd)
Dihydrocodeine 30mg tablets (Medihealth (Northern) Ltd)
Dihydrocodeine 30mg tablets (Phoenix Healthcare Distribution Ltd)
Dihydrocodeine 30mg tablets (Sigma Pharmaceuticals Plc)

Dihydrocodeine 60mg modified-release tablets

Use with caution

Stability notes for Dihydrocodeine 60mg modified-release tablets

Protect from light. No stability data in MCAs available.

Provenance

This recommendation is based on the product dihydrocodeine 60mg prolonged-release tablets (Ennogen IP Ltd).

Suppliers

Dihydrocodeine 60mg modified-release tablets (A A H Pharmaceuticals Ltd)
Dihydrocodeine 60mg modified-release tablets (Alliance Healthcare (Distribution) Ltd)
Dihydrocodeine 60mg modified-release tablets (Ennogen Healthcare International Ltd)

Dihydrocodeine 90mg modified-release tablets

Use with caution

Stability notes for Dihydrocodeine 90mg modified-release tablets

Protect from light. No stability data in MCAs available.

Provenance

This recommendation is based on the product dihydrocodeine 90mg prolonged-release tablets (Ennogen IP Ltd).

Suppliers

Dihydrocodeine 90mg modified-release tablets (A A H Pharmaceuticals Ltd)
Dihydrocodeine 90mg modified-release tablets (Alliance Healthcare (Distribution) Ltd)
Dihydrocodeine 90mg modified-release tablets (Ennogen Healthcare International Ltd)

Dihydrocodeine 120mg modified-release tablets

Use with caution

Stability notes for Dihydrocodeine 120mg modified-release tablets

Protect from light. No stability data in MCAs available.

Provenance

This recommendation is based on the product dihydrocodeine 120mg prolonged-release tablets (Ennogen IP Ltd).

Suppliers

Dihydrocodeine 120mg modified-release tablets (A A H Pharmaceuticals Ltd)
Dihydrocodeine 120mg modified-release tablets (Alliance Healthcare (Distribution) Ltd)
Dihydrocodeine 120mg modified-release tablets (Ennogen Healthcare International Ltd)

What the ratings mean

Compatible
Suitable for use. Keep in MCA for shortest possible time: no more than 5 weeks for non-airtight; 8 weeks for airtight. Use likely to be off-label.
Use with caution
Suitable with mitigations. Keep in MCA for shortest possible time: no more than 5 weeks for non-airtight; 8 weeks for airtight. Use likely to be off-label and supported by limited data.
Incompatible
Medicines under this category are not suitable for use in MCAs.
No stability information
These medicines have not been reviewed by SPS.